PMC full text:
Eur J Cancer. Author manuscript; available in PMC 2011 Sep 18.
Published in final edited form as:
Eur J Cancer. 2011 Sep; 47(13): 1955–1961.
Published online 2011 May 18. doi: 10.1016/j.ejca.2011.04.019Table 2
Sunitinib treatment outcomes.
| Characteristic/group (number of patients) | ASIs* users | ASIs non-users | HR, p |
|---|---|---|---|
| Whole patient group | |||
| n = 44 | n = 83 | ||
| Objective response% (n) | |||
| Partial response/stable disease | 86% (n = 38) | 72% (n = 60) | p = 0.07 |
| Progressive disease** | 14% (n = 6) | 28% (n = 23) | |
| Median progression free survival (months) | 13 | 6 | HR 0.537, p = 0.0055 |
| Median overall survival (months) | 30 | 23 | HR 0.688, p = 0.21 |
| Heng favourable risk | |||
| n = 12 | n = 21 | ||
| Objective response% (n) | |||
| Partial response/stable disease | 100% (n = 12) | 81% (n = 17) | p = 0.29 |
| Progressive disease | 0% (n = 0) | 19% (n = 4) | |
| Median progression free survival (months) | 12 | 6.5 | HR 0.6, p = 0.25 |
| Median overall survival (months) | 20.5 | 17 | HR 0.52, p = 0.26 |
| Heng intermediate risk | |||
| n = 24 | n = 47 | ||
| Objective response% (n) | |||
| Partial response/stable disease | 87% (n = 21) | 68% (n = 32) | p = 0.14 |
| Progressive disease | 13% (n = 3) | 32% (n = 15) | |
| Median progression free survival (months) | 12 | 5 | HR 0.52, p = 0.014 |
| Median overall survival (months) | 21 | 17 | HR 1.1, p = 0.97 |
| Heng poor risk | |||
| n = 8 | n = 15 | ||
| Objective response% (n) | |||
| Partial response/stable disease | 62% (n = 5) | 73% (n = 11) | p = 0.95 |
| Progressive disease | 38% (n = 3) | 27% (n = 4) | |
| Median progression free survival (months) | 12.5 | 7 | HR 0.38, p = 0.06 |
| Median overall survival (months) | 23 | 15 | HR = 0.14, p = 0.18 |
| Patients of the clear cell variety that were naïve to systemic targeted treatment | |||
| n = 32 | n = 55 | ||
| Objective response% (n) | |||
| Partial response/stable disease | 91% (n = 29) | 85% (n = 47) | p = 0.7 |
| Progressive disease | 9% (n = 3) | 15% (n = 8) | |
| Median progression free survival (months) | 12 | 6 | HR = 0.65, p = 0.07 |
| Median overall survival (months) | 21 | 17 | HR = 0., p = 0.78 |
*ASIs = angiotensin system inhibitors.
**At first imaging evaluation within the first 3 months.